How much revenue does Wuhan General Group (China) make?

Wuhan General Group (China) reported $80.38 million in revenue for fiscal year 2012, down 37.0% from $127.50 million in fiscal year 2011.

What companies are similar to Wuhan General Group (China)?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Sentry Petroleum Ltd (SPLM), ObsEva SA (OBSEF), Lords & Company Worldwide Holdings Inc. (LRDSF), James E. Wagner Cultivation Corporation (JWCAF).

Wuhan General Group (China), Inc. (WUHN) Stock

About Wuhan General Group (China), Inc.

Wuhan General Group (China), Inc., a nutraceutical biotechnology company focused on alternative plant-based cannabinoids and psilocybin medical research. The company offers its products for medical applications, including cancer, mental disorders, chronic pain, and others. Wuhan General Group (China), Inc. is headquartered in Reno, Nevada.

At a glance

Wuhan General Group (China) reported revenue of $80.38 million for fiscal year 2012, down 37.0% from fiscal year 2011, and net income of -$11.32 million.

Figures from company filings; latest fiscal year ended December 31, 2012.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.